Sukumar Nagendran

Insider Reports History

Identity 1 identity field
Location
Bannockburn, IL
SEC source record 1 source field
Owner filing signature
/s/ Kamran Alam, Attorney-in-Fact
Source evidence 1 source field
Transaction evidence
Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Sukumar Nagendran

Form 4 holding President and Head of R&D, Director

Taysha Gene Therapies, Inc.

Security class
Employee Stock Option (right to buy)
Shares / value
455,920
Estimated value
Report date
10 Apr 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Solid Biosciences Inc.

Security class
Director Stock Option (Right to Buy)
Shares / value
77,500
Estimated value
Report date
12 Jun 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Sukumar Nagendran

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .